Shots:
In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have selected Dupixent and prepared a curated analysis report for our readers
Dupixent is an interleukin-4 receptor alpha antagonist used for the treatment of multiple indications including atopic dermatitis, asthma, eosinophilic esophagitis, etc.
PharmaShots…
Shots:
Subsequent to our last year’s series titled “Top Performing Drugs of 2021”, PharmaShots presents a list of 12 high revenue-generating drugs
With the ongoing pandemic playing an instrumental role in reshaping the life science industry now and then, it becomes increasingly onerous for the pharmaceutical industry to keep up with the growing global demands…
Shots:
The EMA approved 3 New Chemical Entity (NCE) and 5 Biologic Drugs in January 2023, leading to treatments for patients and advances in the healthcare industry
In January 2023, the major highlights drugs were Xofluza’s Approval for influenza, Dupixent for eosinophilic esophagitis
PharmaShots has compiled a list of a total of 8 new drugs…
Shots:
The pharmaceutical companies have shown continual efforts towards developing enhanced and innovative treatment options to address the unmet needs of patients with disease eradication being the goal of developing these treatments
Advancements in cellular and molecular biology have increased the possibilities for generating new pharmaceutical products imposing major impacts on the prevention, diagnosis, and…

